Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T17228 |
Sabizabulin
ABI-231,VERU-111 |
Microtubule Associated | Cytoskeletal Signaling |
Sabizabulin (ABI-231) 是一种有效且具有口服生物利用度的 α 和 β 微管蛋白抑制剂,可对抗黑色素瘤和前列腺癌细胞系。 Sabizabulin 通过靶向 HPV E6 和 E7 抑制宫颈癌细胞的肿瘤生长和转移表型。 Sabizabulin 显示出抗增殖活性,可用于前列腺癌研究。 | |||
T69557 | ABI-231 HCl | ||
ABI-231 is a potent, orally bioavailable tubulin inhibitor that interacts with the colchicine binding site and is currently undergoing clinical trials for prostate cancer. ABI-231, has an average IC50 = 5.2 nM against panels of melanoma and prostate cancer cell lines, is orally bioavailable, and strongly suppress melanoma tumors in vivo. ABI-231 holds great promise as a new generation of orally available tubulin inhibitor. |